Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | CASP4 | P49662 | 1/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | CASP9 | P55211 | 1/20 | 0.39 |
| ▸ | CASP6 | P55212 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20175319 | 0.92 | GAA (0.43) | GAALMNAALDH1A1MAPTCHRNB4 | |
| SCHEMBL5518656 | 0.89 | ALDH1A1 (0.42) | GAALMNAALDH1A1MAPTAR | |
| SCHEMBL17505042 | 0.87 | ALDH1A1 (0.42) | GAALMNAALDH1A1MAPTCHRNB4 | |
| SCHEMBL17505037 | 0.87 | MAPT (0.40) | GAALMNAALDH1A1MAPTCHRNB4 | |
| SCHEMBL499016 | 0.86 | NOS3 (0.48) | ALDH1A1MAPTCHRNB4CHRNA3PIK3CD | |
| SCHEMBL20175322 | 0.86 | CHRNB4 (0.41) | LMNAALDH1A1MAPTCHRNB4CHRNA3 | |
| SCHEMBL17505044 | 0.85 | ALDH1A1 (0.50) | GAALMNAALDH1A1MAPTHTT | |
| SCHEMBL20175320 | 0.85 | ALDH1A1 (0.41) | GAALMNAALDH1A1MAPTCHRNB4 | |
| SCHEMBL499372 | 0.85 | ALDH1A1 (0.47) | GAALMNAALDH1A1MAPTMEN1 | |
| SCHEMBL5519181 | 0.83 | MAPT (0.47) | GAALMNAALDH1A1MAPTAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180141922-A1 | BENZOXAZINE DERIVATIVES AND USE IN HAIR DYEING | L'OREAL (FR) | 2018-05-24 | — | — | US | disclosed |
| US-20170327690-A1 | CATIONIC BENZOXAZINE DERIVATIVES AND USE IN HAIR DYEING | OREAL (FR) | 2017-11-16 | — | — | US | disclosed |
| US-20070167445-A1 | Androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS, INC. | 2007-07-19 | — | — | US | disclosed |
| EP-1212330-B1 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARM INC (US) | 2006-04-19 | — | — | EP | disclosed |
| US-20030186970-A1 | Androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS, INC, | 2003-10-02 | — | — | US | disclosed |
| US-6462038-B1 | SUCH AS 1,2,3,6-TETRAHYDRO-1-METHYL-9-(TRIFLUOROMETHYL)-7H-(1,4)OXAZINO(3,2 -G)QUINOLIN-7-ONE; NONSTEROIDAL, HIGH AFFINITY AND SPECIFICITY ANTAGONISTS AND AGONISTS OR PARTIAL AGONISTS, I.E. PARTIAL AND/OR TISSUE SPECIFIC ACTIVATORS | LIGAND PHARMACEUTICALS, INC. | 2002-10-08 | — | — | US | disclosed |
| WO-2001016139-A9 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARM INC (US) | 2002-09-19 | — | — | WO | disclosed |
| EP-1212330-A1 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001016139-A1 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2001-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141922-A1 | BENZOXAZINE DERIVATIVES AND USE IN HAIR DYEING | XDH, KRT18, CYC1 | GAA 4749/4885LMNA 172/4885ALDH1A1 1230/4885 |
| US-20030186970-A1 | Androgen receptor modulator compounds and methods | AR, NR5A1, FSHR | GAA 4776/4885LMNA 3642/4885ALDH1A1 1492/4885 |
| US-20170327690-A1 | CATIONIC BENZOXAZINE DERIVATIVES AND USE IN HAIR DYEING | TYR, CAT, CYC1 | GAA 2485/4885LMNA 1278/4885ALDH1A1 199/4885 |
| US-20070167445-A1 | Androgen receptor modulator compounds and methods | AR, NR5A1, FSHR | GAA 4776/4885LMNA 3642/4885ALDH1A1 1492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.